Publications of Linda Vona-Davis Laboratory

Khouj Y, Dawson J, Coad J, Vona-Davis LC. Hyperspectral imaging and K-means classification for histologic evaluation of ductal carcinoma in situ. Fron Oncol. 2018 Feb7:8:17. PMID: 29468139.   

Mattes MD, Swart E, Markwell SM, Wen S, Vona-Davis L. Methods of academic course planning for cancer biology PhD students to enhance knowledge of clinical oncology. Cancer Research 2017;77(18):4741-4744.PMID: 28729414.  

Cost of hospitalization for infantile pyloric stenosis.
Hajiran CJ, Hobbs GR, Vona-Davis LC, Nakayama DK.
Am Surg. 2016;82(1):3-5.

High-fat, high-calorie diet enhances mammary carcinogenesis and local inflammation in MMTV-PyMT mouse model of breast cancer.
Cowen S, McLaughlin SL, Hobbs GR, Coad JE, Martin KH, Olfert IM, Vona-Davis LC.
Cancers (Basel). 2015;7(3):1125-1142.


The interactions of obesity, inflammation and insulin resistance in breast cancer.
Rose DP, Gracheck PJ, Vona-Davis LC.
Cancers (Basel). 2015;7(4):2147-2168.


Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile.
Swisher AK, Abraham J, Bonner D, Gilleland D, Hobbs GR, Kurian S, Yanosik MA, Vona-Davis LC.
Support Care Cancer. 2015;23(10):2995-3003.


Essential components of cancer education.
Welch DR, Antalis TM, Burnstein K, Vona-Davis LC, Jensen RA, Nakshatri H, Riegel AT, Spitz DR, Watson DK, Weiner GJ, Cancer Biology Training Consortium.
Cancer Res. 2015;75(24):5202-5205.


Loss of adipocyte VEGF impairs endurance exercise capacity in mice.
Zachwieja NJ, O'Connell GC, Stricker JC, Allen J, Vona-Davis LC, Bryner R, Mandler W, Olfert IM.
Med Sci Sports Exerc. 2015;47(11):2329-2339.


"Don't Know" and accuracy of breast cancer risk perceptions among Appalachian women attending a mobile mammography program: implications for educational interventions and patient empowerment.
Lemasters TJ, Madhavan SS, Atkins E, Vyas A, Remick SC, Vona-Davis LC.
J Cancer Educ. 2014;29(4):669-679.

Biochemical and molecular mechanisms for the association between obesity, chronic Inflammation, and breast cancer.
Rose DP, Vona-Davis LC.
Biofactors. 2014;40(1):1-12.

Breast cancer pathology, receptor status, and patterns of metastasis in a rural Appalachian population.
Vona-Davis LC, Rose DP, Gadiyaram V, Ducatman BS, Hobbs GR, Hazard HW, Kurian S, Abraham J.
J Cancer Epidemiol. 2014;2014:170634


The obesity-inflammation-eicosanoid axis in breast cancer.
Vona-Davis LC, Rose DP.
J Mammary Gland Biol Neoplasia. 2013;18(3-4):291-307.

Adipocytes as a critical component of the tumor microenvironment.
Vona-Davis LC, Gibson LF.
Leuk Res. 2013;37(5):483-484.


The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.
Rose DP, Vona-Davis LC.
Endocr Relat Cancer. 2012;19(6):R225-R241.

Type 2 diabetes and obesity metabolic interactions: Common factors for breast cancer risk and novel approaches to prevention and therapy.
Vona-Davis LC, Rose DP.
Curr Diabetes Rev. 2012;8(1):116-130.

Factors influencing adherence to mammography screening guidelines in Appalachian women participating in a mobile mammography program.
Vyas A, Madhavan SS, Lemasters T, Atkins E, Gainor SJ, Kennedy S, Kelly KM, Vona-Davis LC, Remick SC.
J Community Health. 2012;37(3):632-646.

Bonnie's Bus: first year accomplishments and future directions.
Faulkner SL, Kennedy S, Gainor SJ, Conn ME, Allen AR, Brown PK, Madhavan SS, Vona-Davis LC, Shreiman J, Remick SC.
J Womens Health. 2011;20(2):464

Interaction between menopausal status and obesity in affecting breast cancer risk.
Rose DP, Vona-Davis LC.
Maturitas. 2010;66(1):33-38.

Triple-negative breast cancer in West Virginia.
Abraham J, Flanagan M, Hazard HW, Jubelirer SJ, Tirona MT, Vona-Davis LC.
WV Med J. 2009;105 Spec No:54-59.

Influence of obesity on breast cancer receptor status and prognosis.
Rose DP, Vona-Davis LC.
Expert Rev Anticancer Ther. 2009;9(8):1091-1101.

The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.
Vona-Davis LC, Rose DP.
J Womens Health (Larchmt). 2009;18(6):883-893.

Angiogenesis, adipokines and breast cancer.
Vona-Davis LC, Rose DP.
Cytokine Growth Factor Rev. 2009;20(3):193-201.

Triple-negative breast cancer and obesity in a rural Appalachian population.
Vona-Davis LC, Rose DP, Hazard HW, Howard-McNatt M, Adkins FC, Partin J, Hobbs GR.
Cancer Epidemiol Biomarkers Prev. 2008;17(12):3319-3324.

Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer.
Vona-Davis LC, Howard-McNatt M, Rose DP.
Obes Rev. 2007;8(5):395-408.

PYY and the pancreas: inhibition of tumor growth and inflammation.
Vona-Davis LC, McFadden DW.
Peptides. 2007;28(2):334-338.

Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression.
Vona-Davis LC, Rose DP.
Endocr Relat Cancer. 2007;14(2):189-206.

NPY family of hormones: clinical relevance and potential use in gastrointestinal disease.
Vona-Davis LC, McFadden DW.
Curr Top Med Chem. 2007;7(17):1710-1720.

Leptin receptor expression and cell signaling in breast cancer.
Frankenberry KA, Skinner HD, Somasundar P, McFadden DW, Vona-Davis LC.
Int J Oncol. 2006;28(4):985-993.

Peptide YY reverses TNF-alpha induced transcription factor binding of interferon regulatory factor-1 and p53 in pancreatic acinar cells.
Rizvi IA, Robinson K, McFadden DW, Riggs DR, Jackson BJ, Vona-Davis LC.
J Surg Res. 2006;136(1):25-30.

Peptide YY attenuates STAT1 and STAT3 activation induced by TNF-alpha in acinar cell line AR42J.
Robinson K, Vona-Davis LC, Riggs DR, Jackson BJ, McFadden DW.
J Am Coll Surg. 2006;202(5):788-796.

Inferior vena cava filter placement in late-stage cancer.
Schunn C, Schunn GB, Hobbs GR, Vona-Davis LC, Waheed U.
Vasc Endovascular Surg. 2006;40(4):287-294.

In vitro effects of keyhole limpet hemocyanin in breast and pancreatic cancer in regards to cell growth, cytokine production, and apoptosis.
Riggs DR, Jackson BJ, Vona-Davis LC, Nigam A, McFadden DW.
Am J Surg. 2005;189(6):680-684.

Inositol hexaphosphate (IP6): a novel treatment for pancreatic cancer.
Somasundar P, Riggs DR, Jackson BJ, Cunningham CA, Vona-Davis LC, McFadden DW.
J Surg Res. 2005;126(2):199-203.

Expression of STAT3 and SOCS3 in pancreatic acinar cells.
Vona-Davis LC, Frankenberry KA, Waheed U, Peterson E, McFadden DW.
J Surg Res. 2005;127(1):14-20.

MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro.
Vona-Davis LC, Frankenberry KA, Cunningham CA, Riggs DR, Jackson BJ, Szwerc MF, McFadden DW.
J Surg Res. 2005;127(1):53-58.

Leptin induces cell migration and the expression of growth factors in human prostate cancer cells.
Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC.
Am J Surg. 2004;188(5):560-565.

Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro.
McFadden DW, Riggs DR, Jackson BJ, Vona-Davis LC.
Am J Surg. 2004;188(5):516-519.

COX-2 inhibition and cancer: experimental findings and clinical correlates.
Roberts EG, Vona-Davis LC, Riggs DR, Jackson BJ, Hohseni H, Kandzari SJ, McFadden DW.
WV Med J. 2004;100(3):96-101.

Prostate cancer cell proliferation is influenced by leptin.
Somasundar P, Frankenberry KA, Skinner HD, Vedula G, McFadden DW, Riggs DR, Jackson BJ, VanGilder RL, Hileman SM, Vona-Davis LC.
J Surg Res. 2004;118(1):71-82.

Leptin is a growth factor in cancer.
Somasundar P, McFadden DW, Hileman SM, Vona-Davis LC.
J Surg Res. 2004;116(2):337-349.

Peptide YY attenuates transcription factor activity in tumor necrosis factor-alpha-induced pancreatitis.
Vona-Davis LC, Yu A, Magabo K, Evans T, Jackson BJ, Riggs DR, McFadden DW.
J Am Coll Surg. 2004;199(1):87-95.

Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Vona-Davis LC, Riggs DR, Jackson BJ, McFadden DW.
J Surg Res. 2004;119(2):143-148.

Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin.
Vona-Davis LC, Vincent T, Zulfiqar S, Jackson BJ, Riggs DR, McFadden DW.
J Gastrointest Surg. 2004;8(8):1018-1023.

Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma.
McFadden DW, Riggs DR, Jackson BJ, Vona-Davis LC.
Am J Surg. 2003;186(5):552-555.

Phosphocreatine restores high-energy phosphates in ischemic myocardium: implication for off-pump cardiac revascularization.
Prabhakar G, Vona-Davis LC, Murray D, Lakhani P, Murray GF.
J Am Coll Surg. 2003;197(5):786-791.

Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms.
Somasundar P, Riggs DR, Jackson BJ, Vona-Davis LC, McFadden DW.
Am J Surg. 2003;186(5):575-578.

Differential effects of leptin on cancer in vitro.
Somasundar P, Yu AK, Vona-Davis LC, McFadden DW.
J Surg Res. 2003;113(1):50-55.

Modulation of interleukin-6 in cardiac myoblasts during endotoxemia.
Vona-Davis LC, Zhu X, Yu AK, McFadden DW.
J Surg Res. 2003;112(1):91-96.

In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin.
Riggs DR, Jackson BJ, Vona-Davis LC, McFadden DW.
J Surg Res. 2002;108(2):279-284.

Cardiac response to nitric oxide synthase inhibition using aminoguanidine in a rat model of endotoxemia.
Vona-Davis LC, Wearden PD, Hill J, Hill RC.
Shock. 2002;17(5):404-410.

Effect of creatine monohydrate on cardiac function in a rat model of endotoxemia.
Vona-Davis LC, Wearden PD, Karne NH, Hill RC.
J Surg Res. 2002;103(1):1-7.

Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor.
Yu A, Somasundar P, Balsubramaniam A, Rose AT, Vona-Davis LC, McFadden DW.
J Surg Res. 2002;105(1):65-68.